Signal Shares will be carrying out system maintenance from 6pm on 28 May until 6am on 31 May. If you are planning to cast your AGM votes through Signal Shares please ensure this is done in advance or between 6am on the 31 May and 12pm on the 1 June.
Regenerative medicine is an innovative and expanding field, researching the potential of tissue engineering to offer a natural recovery by triggering a response through the body’s own cells, and enable the natural regeneration of the patient’s own tissues.
We use our innovative platform technologies to address clinical needs in the regenerative medicine market. Our technologies dCELL® and BioRinse™ are complementary bone and soft tissue platforms.
We focus on the development of regenerative products utilising our two platform technologies to transform the treatment of patients and provide differentiated clinical outcomes in key clinical areas.